26 April 2019
Visiongain has launched a new pharma report Global Antibacterial Drugs Market Report : Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems and Others.
The demand for antibacterial drugs will continue as bacterial infections are among the most common diseases worldwide. However, strong efforts to restrict antibiotic prescribing in developed and emerging markets will not only reduce bacterial resistance but will also restrain growth. The development of novel therapies, on the other hand, will be driven by increased government investment and funding from other public bodies.
The lead analyst of the report commented "As with other sectors of the pharmaceutical industry, future antibacterial drug development will be driven by innovation from small bio pharmaceutical companies, Visiongain believes.
Many of the most novel products in the development pipeline have come from small companies targeting new treatment pathways or mechanisms of action. Increased demand and funding from governments for new antibacterial drugs will benefit these small companies over the coming 10 years."
Leading companies featured in the report include Adenium Biotech ApS, Allecra Therapeutics GmbH, AstraZeneca, Bayer, BioVersys AG, Eli Lilly. GlaxoSmithKline (GSK), Merck & Co., Novartis, Pfizer and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
14 July 2021
Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.